ROBERT R. RUFFOLO JR., PH.D.
To the editor: The review by Leier and Unverferth (1) detailing 5 years of clinical experience with the inotropic agent, dobutamine, is an invaluable reference source. There are two points raised in the article that I believe need to be addressed further. The authors indicate that dobutamine is a strong beta1-adrenoceptor agonist and only a mild beta2- and alpha1-adrenoceptor agonist, and that the inotropic activity of dobutamine is mediated by stimulation of myocardial beta1-adrenoceptors. Recent animal studies show that the ability of dobutamine to stimulate alpha1- and beta2-adrenoceptors is at least as great as its ability to stimulate beta1-adrenoceptors (2,
RUFFOLO RR. The Mechanism of Action of Dobutamine. Ann Intern Med. ;100:313–314. doi: 10.7326/0003-4819-100-2-313
Download citation file:
Published: Ann Intern Med. 1984;100(2):313-314.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use